Emerging treatments for insomnia

CPD
By
AP Staff
-

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5 ed. Washington DC: Ameican Psychiatric Publishing; 2022.
  2. Rosenberg RP, Benca R, Doghramji P, et al. A 2023 update on managing insomnia in primary care: insights from an expert consensus group. Prim Care Companion CNS Disord 2023;25(1).
  3. Vargas I, Nguyen AM, Muench A, et al. Acute and chronic insomnia: what has time and/or hyperarousal got to do with It? Brain Sci 2020;10(2).
  4. Reynolds Aea. Chronic insomnia disorder in Australia: A report to the Sleep Health Foundation. 2019. At: www.sleepprimarycareresources.org.au/insomnia/epidemiology#footnote-1
  5. Falup-Pecurariu C, Diaconu Ș, Țînț D, et al. Neurobiology of sleep (Review). Exp Ther Med 2021;21(3):272.
  6. Mojsa-Kaja J, Ivcevic Z. Emotion regulation strategies and mental health symptoms during COVID-19: the mediating role of insomnia. Int J Occup Med Environ Health 2023;36(1):1519.
  7. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005;437(7063):125763.
  8. Altena E, Ellis J, Camart N, et al. Mechanisms of cognitive behavioural therapy for insomnia. J Sleep Res 2023;32(6):e13860.
  9. Trauer JM, Qian MY, Doyle JS, et al. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med 2015;163(3):191204.
  10. Insomnia. Therapeutic Guidelines; [updated Feb 2025].  At: https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Psychotropic&topicfile=insomnia-adults&guidelinename=Psychotropic&sectionId=toc_d1e588#toc_d1e588
  11. Morin CM, Vallières A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. Jama 2009;301(19):200515.
  12. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part B: Benzodiazepines. 2019. At: www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence/part-b
  13. Jang SH, Kwon HG. The ascending reticular activating system from pontine reticular formation to the hypothalamus in the human brain: a diffusion tensor imaging study. Neurosci Lett 2015;590:5861.
  14. Jones BE. Arousal and sleep circuits. Neuropsychopharmacology 2020;45(1):620.
  15. Pizza F, Barateau L, Dauvilliers Y, et al. The orexin story, sleep and sleep disturbances. J Sleep Res 2022;31(4):e13665.
  16. Tamaki M, Bang JW, Watanabe T, et al. Night watch in one brain hemisphere during sleep associated with the first-night effect in humans. Curr Biol 2016;26(9):11904.
  17. Siclari F, Tononi G. Local aspects of sleep and wakefulness. Curr Opin Neurobiol 2017;44:2227.
  18. Pagel JF, Pandi-Perumal SR, Monti JM. Treating insomnia with medications. Sleep Science and Practice 2018;2(1):5.
  19. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63(11):222746.
  20. Wong CK, Marshall NS, Grunstein RR, et al. Spontaneous adverse event reports associated with zolpidem in the United States 20032012. J Clin Sleep Med 2017;13(2):22334.
  21. Leong CWY, Leow JWS, Grunstein RR, et al. A systematic scoping review of the effects of central nervous system active drugs on sleep spindles and sleep-dependent memory consolidation. Sleep Med Rev 2022;62:101605.
  22. Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol 2018;175(16):31909.
  23. Choi K, Lee YJ, Park S, et al. Efficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses. Sleep Medicine Reviews 2022;66:101692.
  24. Marupuru S, Arku D, Campbell AM, et al. Use of melatonin and/on ramelteon for the treatment of insomnia in older adults: a systematic review and meta-analysis. J Clin Med 2022;11(17).
  25. Everitt H, Baldwin DS, Stuart B, et al. Antidepressants for insomnia in adults. Cochrane Database of Systematic Reviews 2018;5(5):Cd010753.
  26. Wichniak A, Wierzbicka A, Walęcka M, et al. Effects of antidepressants on sleep. Curr Psychiatry Rep 2017;19(9):63.
  27. Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26(6):675700.
  28. Kim WJ, Kim HS. Emerging and upcoming therapies in insomnia. Transl Clin Pharmacol 2024;32(1):117.
  29. Yardley J, Kärppä M, Inoue Y, et al. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Medicine 2021;80:33342.
  30. Rossi S, ed. Australian Medicines Handbook. 2025. At: https://amhonline.amh.net.au/
  31. Uslaner JM, Tye SJ, Eddins DM, et al. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition. Sci Transl Med 2013;5(179):179ra44.
  32. Parks GS, Warrier DR, Dittrich L, et al. The dual hypocretin receptor antagonist almorexant is permissive for activation of wake-promoting systems. Neuropsychopharmacology 2016;41(4):114455.
  33. Tannenbaum PL, Tye SJ, Stevens J, et al. Inhibition of orexin signaling promotes sleep yet preserves salient arousability in monkeys. Sleep 2016;39(3):60312.
  34. Magliocca M, Koopmans I, Vaillant C, et al. Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function. J Psychopharmacol 2025;39(3):22332.
  35. Muehlan C, Roch C, Vaillant C, et al. The orexin story and orexin receptor antagonists for the treatment of insomnia. J Sleep Res 2023;32(6):e13902.
  36. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13(5):46171.
  37. Clark JW, Brian ML, Drummond SPA, et al. Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Med Rev 2020;53:101332.
  38. Carpi M, Palagini L, Fernandes M, et al. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities. Neuropharmacology 2024;245:109815.
  39. Herring WJ, Roth T, Krystal AD, et al. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2019;28(2):e12782.
  40. Sharma R, Bansal P, Saini L, et al. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA(A) receptors. Pharmacol Biochem Behav 2024;238:173734.
  41. Saini B, Collins M. The quest for safer benzodiazepines for use in insomnia, where are we at? Sleep 2024;47(2).
  42. Kim HK, Yang KI. Melatonin and melatonergic drugs in sleep disorders. Transl Clin Pharmacol 2022;30(4):16371.
  43. Maruani J, Reynaud E, Chambe J, et al. Efficacy of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults: A systematic review and meta-analysis. J Sleep Res 2023;32(6):e13939.
  44. Zisapel N. Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs 2015;24(3):40111.
  45. Whiteside GT, Kyle DJ, Kapil RP, et al. The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia. J Clin Invest 2024;134(1).